348 A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204, GOG 3038, ENGOT-en12/NOGGO)

• Brian Slomovitz,
• Bradley Monk,
• Katherine Moxley,
• Nadeem Ghali,
• Justyna Fronczek Sokol

Affiliations

Brian Slomovitz

Division of Gynecologic Oncology, Broward Health Medical Center, Fort Lauderdale, Florida, USA

Bradley Monk

2Saint Joseph’s Hospital and Medical Center, Phoenix, AZ, USA

Katherine Moxley

3University of Oklahoma Health Sciences, Oklahoma City, OK, USA

Nadeem Ghali

4Incyte Corporation, Wilmington, DE, USA

Justyna Fronczek Sokol

5Incyte Biosciences International Sàrl, Morges, Switzerland